For Lymphedema Awareness Month, join millions of patients and healthcare professionals in recognizing and advocating for the improvement of patient care and access for those at-risk or suffering from lymphedema. Click to learn more about the 5-things you can do to get involved!
Advances in medical treatment have dramatically improved cancer care and survivorship. However, of the nearly 17 million cancer survivors living in the U.S., it is estimated that one in three of those treated for the cancers below will develop lymphedema.1,2 Those most at risk are patients who undergo surgery, radiation therapy or Taxane-based chemotherapy.
Know your L-Dex® score
Early Detection Starts with an L-Dex Score. Previously, cancer survivors were not routinely monitored, but with L-Dex, your healthcare provider has a tool that aids in early detection of lymphedema. L-Dex is a measurement of fluid buildup in your at-risk limb compared to a healthy limb. It uses noninvasive bioimpedance spectroscopy (BIS), which is capable of detecting fluid changes as small as 2.4 tablespoons (36 ml) and takes less than 30 seconds to complete. For best results, at-risk patients receive a baseline measurement before cancer treatment begins and are then monitored regularly after treatment.
See how a Lymphedema Prevention Program can improve clinical outcomes for secondary lymphedema:
Watch how a surveillance model of care can help cancer patients avoid progression of secondary lymphedema:
1. Herd-Smith, A., et al., Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer, 2001. 92(7): p. 1783-7
2. Shah C, et al. Bioimpedance Spectroscopy for Breast Cancer Related Lymphedema Assessment: Clinical Practice Guidelines. The Breast Journal 2016;DOI: 10.1111/tbj.12647.
ImpediMed’s bioimpedance spectroscopy (BIS) devices have been studied and clinically validated in the areas of lymphedema, heart failure, body composition and veterinary BIS research.